Since BPDCN cells have a higher sensitivity to the inhibition of BRD4, which has been shown to depend on TCF412, we also demonstrated that RUNX2 is one of the crucial targets in the setting of BRD4 inhibition in BPDCN cells. Here, RUNX2 is linked to CD4+/CD56+ hematodermic neoplasm.